Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 3/20 | 0.48 |
| ▸ | MAP2K1 | Q02750 | 16/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAP2K2 | P36507 | 3/20 | 0.41 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.40 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12083476 | 0.89 | CYP2C9 (0.45) | CYP2C9MAP2K1KCNH2CYP2C19CYP3A4 | |
| SCHEMBL12083414 | 0.88 | MAP2K1 (0.50) | MAP2K1MAP2K2MAP2K5 | |
| SCHEMBL12083390 | 0.86 | ECE1 (0.36) | CYP2C9MAP2K1KCNH2CYP2C19 | |
| SCHEMBL3039673 | 0.86 | MAP2K1 (0.42) | CYP2C9MAP2K1KCNH2CYP2C19MAP2K2 | |
| SCHEMBL12083411 | 0.86 | KCNH2 (0.38) | CYP2C9MAP2K1KCNH2CYP2C19 | |
| SCHEMBL12083468 | 0.84 | CYP2C9 (0.47) | CYP2C9MAP2K1KCNH2CYP2C19CYP3A4 | |
| SCHEMBL12083429 | 0.83 | MAP2K1 (0.44) | CYP2C9MAP2K1KCNH2CYP2C19CYP3A4 | |
| SCHEMBL3024357 | 0.82 | MAPT (0.48) | — | |
| SCHEMBL3033844 | 0.82 | CCR2 (0.40) | — | |
| SCHEMBL12083459 | 0.82 | KCNH2 (0.45) | CYP2C9MAP2K1KCNH2CYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2164850-B1 | N-SUBSTITUTED AZAINDOLES AND METHODS OF USE | GENENTECH INC (US) | 2016-01-13 | — | — | EP | disclosed |
| EP-2164850-B1 | N-SUBSTITUTED AZAINDOLES AND METHODS OF USE | GENENTECH INC (US) | 2016-01-13 | — | — | EP | disclosed |
| US-8258152-B2 | N-substituted azaindoles and methods of use | GENENTECH, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-8258152-B2 | N-substituted azaindoles and methods of use | GENENTECH, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-8258152-B2 | N-substituted azaindoles and methods of use | GENENTECH, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-20100216768-A1 | N-SUBSTITUTED AZAINDOLES AND METHODS OF USE | GENENTECH, INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100216768-A1 | N-SUBSTITUTED AZAINDOLES AND METHODS OF USE | GENENTECH, INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100216768-A1 | N-SUBSTITUTED AZAINDOLES AND METHODS OF USE | GENENTECH, INC. | 2010-08-26 | — | — | US | disclosed |
| WO-2008157179-A2 | N-SUBSTITUTED AZAINDOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216768-A1 | N-SUBSTITUTED AZAINDOLES AND METHODS OF USE | MKI67, CCNI, CDKN1A | CYP2C9 3533/4885MAP2K1 24/4885KCNH2 3802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.